45 Abstracts Demonstrate the Value of the nCounter Platform for
Studies Indicate the Clinical Relevance of the Tumor Inflammation Signature for Multiple Immunotherapies
"The scope of nCounter-based research being presented at this year's SITC conference demonstrates our scientific and commercial momentum
in immuno-oncology," said
At least 45 abstracts using NanoString's nCounter platform will be presented at the SITC Annual Meeting, being held in
Nineteen studies used NanoString's PanCancer Series of panels to explore biomarkers associated with response to immunotherapy. Fourteen of these studies incorporate NanoString's best-selling
The PanCancer IO 360 Panel studies provide initial evidence of positive association between the Tumor Inflammation Signature scores and clinical response to different immuno-oncology agents including nivolumab, ipilimumab, pembrolizumab and entinostat.
Five studies cover the use of NanoString's Digital Spatial Profiling (DSP) platform in immuno-oncology research. DSP allows for digital quantification of protein from discrete regions of FFPE tissue in an automated and multiplex format. DSP will become widely available with the launch of a new instrument planned for late 2018, and in the meantime is available under a Technology Access Program.
Two studies cover the use of 3D Biology™ panels and demonstrate the utility of the nCounter platform. NanoString's 3-D Flow™ technology provides detailed molecular profiles of T cell populations, and enables unique, simultaneous analysis of high-plex protein and RNA data. 3D Biology and 3D Flow approaches can be used to characterize baseline immunological state and response to stimulation, which may be useful for profiling mechanisms of action or therapeutic response.
At the 2017 SITC Annual Meeting,
Below is a summary of abstracts co-authored by
|05||A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand||https://www.sitcancer.org/2017/abstracts/titles/oral|
|019||ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)||https://www.sitcancer.org/2017/abstracts/titles/oral|
|P40||Deep proteomic and transcriptomic analysis of sorted T cells with a simple, integrated workflow||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P43||Assessment of Pharmacodynamic Effects of Immuno-Oncology Agents in Cynomolgus Monkeys using High-Content Gene Expression Profiling||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P64||Analytical Validation of Digital Spatial Profiling - a novel approach for multiplexed characterization of protein distribution and abundance in FFPE tissue sections||
|P65||Spatially-resolved, multiplexed digital characterization of protein abundance in FFPE tissue sections: application in preclinical mouse models||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P66||Digital spatial profiling platform allows both spatially-resolved, multiplexed measurement of solid tumor and immune-associated protein distribution and abundance using a single FFPE tissue section||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P72||Analysis of biomarkers from a cohort of advanced melanoma patients previously exposed to immune checkpoint inhibition treated with entinostat (ENT) and pembrolizumab (PEMBRO).||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P73||First-in-human neoadjuvant study of the immunogenomic impact of the oral IDO inhibitor epacadostat (INCB024360) on the tumor microenvironment of advanced ovarian cancer||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P98||Immunological profiling of baseline and resected biopsies from locally/regionally advanced/recurrent melanoma treated with neoadjuvant combination ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2B||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P99||Biomarker analysis from the OpACIN trial (Neo-/adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma)||
|P100||Pretreatment gene expression correlation with clinical response to pembrolizumab or nivolumab in metastatic melanoma||https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring|
|P383||Molecular and immune characterization of melanoma metastases with heterogeneous PTEN expression||https://www.sitcancer.org/2017/abstracts/titles/mechanisms-resistance-immunotherapy|
|P485||Use of the NanoString Gene Expression Profiling Platform to Capture the Immunological Status of the Leukemia Microenvironment||https://www.sitcancer.org/2017/abstracts/titles/tumor-microenvironment|
|P512||Deep immunoprofiling of rare T-cell populations from clinical samples||https://www.sitcancer.org/2017/abstracts/titles/late-breaking|
|P524||Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1||
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the capabilities of the company's current and future products and the timing of future product launches. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the impact of competition; as well as the other risks set forth in the company's filings with the
Vice President, Investor Relations & Corporate Communications
News Provided by Acquire Media